JP2021530251A5 - - Google Patents

Info

Publication number
JP2021530251A5
JP2021530251A5 JP2021526401A JP2021526401A JP2021530251A5 JP 2021530251 A5 JP2021530251 A5 JP 2021530251A5 JP 2021526401 A JP2021526401 A JP 2021526401A JP 2021526401 A JP2021526401 A JP 2021526401A JP 2021530251 A5 JP2021530251 A5 JP 2021530251A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021526401A
Other languages
English (en)
Japanese (ja)
Other versions
JP7513605B2 (ja
JP2021530251A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/042493 external-priority patent/WO2020018852A2/en
Publication of JP2021530251A publication Critical patent/JP2021530251A/ja
Publication of JP2021530251A5 publication Critical patent/JP2021530251A5/ja
Priority to JP2024103530A priority Critical patent/JP2024133536A/ja
Application granted granted Critical
Publication of JP7513605B2 publication Critical patent/JP7513605B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526401A 2018-07-18 2019-07-18 新規な抗体ならびにそれを調製および使用するための方法 Active JP7513605B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024103530A JP2024133536A (ja) 2018-07-18 2024-06-27 新規な抗体ならびにそれを調製および使用するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862700174P 2018-07-18 2018-07-18
US62/700,174 2018-07-18
US201962792798P 2019-01-15 2019-01-15
US62/792,798 2019-01-15
PCT/US2019/042493 WO2020018852A2 (en) 2018-07-18 2019-07-18 Novel antibodies and methods for making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024103530A Division JP2024133536A (ja) 2018-07-18 2024-06-27 新規な抗体ならびにそれを調製および使用するための方法

Publications (3)

Publication Number Publication Date
JP2021530251A JP2021530251A (ja) 2021-11-11
JP2021530251A5 true JP2021530251A5 (cg-RX-API-DMAC7.html) 2023-03-10
JP7513605B2 JP7513605B2 (ja) 2024-07-09

Family

ID=69165232

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021526401A Active JP7513605B2 (ja) 2018-07-18 2019-07-18 新規な抗体ならびにそれを調製および使用するための方法
JP2024103530A Pending JP2024133536A (ja) 2018-07-18 2024-06-27 新規な抗体ならびにそれを調製および使用するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024103530A Pending JP2024133536A (ja) 2018-07-18 2024-06-27 新規な抗体ならびにそれを調製および使用するための方法

Country Status (5)

Country Link
US (2) US11505618B2 (cg-RX-API-DMAC7.html)
EP (1) EP3824096A4 (cg-RX-API-DMAC7.html)
JP (2) JP7513605B2 (cg-RX-API-DMAC7.html)
CN (1) CN112513093B (cg-RX-API-DMAC7.html)
WO (1) WO2020018852A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824096A4 (en) * 2018-07-18 2022-04-20 AskGene Pharma Inc. NOVEL ANTIBODIES AND METHODS FOR THE PRODUCTION AND USE THEREOF
JP7840511B2 (ja) 2019-02-01 2026-04-06 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗クローディン18抗体及びそれらの使用の方法
US20230312704A1 (en) * 2020-02-10 2023-10-05 Shanghai Escugen Biotechnology Co., Ltd. Cldn18.2 antibody and use thereof
CR20220580A (es) * 2020-05-15 2023-04-11 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
KR102916382B1 (ko) * 2020-07-13 2026-01-21 상하이 준스 바이오사이언스 컴퍼니 리미티드 항-cldn-18.2 항체 및 그 용도
CN111808194B (zh) * 2020-07-13 2021-04-20 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
EP4222174A4 (en) * 2020-09-30 2025-02-12 Nanjing GenScript Biotech Co., Ltd. Antibodies targeting human claudin 18.2 and uses thereof
CN114504642B (zh) * 2020-11-17 2026-03-27 江苏奥赛康生物医药有限公司 一种含抗cldn18.2抗体的液体药物组合物
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
KR20230124037A (ko) 2020-12-23 2023-08-24 소티오 바이오테크 에이.에스. 종양 특이적 claudin 18.2 항체-약물 접합체
CN114805571B (zh) * 2021-01-28 2023-08-25 广西鹭港生物医药科技有限公司 抗cldn18.2抗体及其应用
WO2022206975A1 (zh) * 2021-04-02 2022-10-06 原启生物科技(上海)有限责任公司 Cldn18.2抗原结合蛋白及其用途
CN115611983A (zh) * 2021-07-14 2023-01-17 三优生物医药(上海)有限公司 Cldn18.2结合分子及其用途
WO2024137619A1 (en) 2022-12-20 2024-06-27 Bolt Biotherapeutics, Inc. Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
EP4653017A1 (en) 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
CN121464158A (zh) * 2023-05-22 2026-02-03 西雅图免疫公司 抗Claudin18.2抗体及其制备和使用方法
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
CN122028934A (zh) * 2023-10-16 2026-05-12 江苏奥赛康生物医药有限公司 Cldn18_2抗体与化学治疗药物的组合及其应用
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技(上海)有限公司 一种抗体偶联药物及其用途
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2026050213A1 (en) 2024-08-27 2026-03-05 Usbolt Biotherapeutics, Inc. Tlr agonist immunoconjugates and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2018026742A1 (en) * 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
WO2018054484A1 (en) 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
CA3115461A1 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
EP3824096A4 (en) * 2018-07-18 2022-04-20 AskGene Pharma Inc. NOVEL ANTIBODIES AND METHODS FOR THE PRODUCTION AND USE THEREOF

Similar Documents

Publication Publication Date Title
JP2024167313A5 (cg-RX-API-DMAC7.html)
JP2020508655A5 (cg-RX-API-DMAC7.html)
JP2023504016A5 (cg-RX-API-DMAC7.html)
JP2021522162A5 (cg-RX-API-DMAC7.html)
JP2015163068A5 (cg-RX-API-DMAC7.html)
JP2010502183A5 (cg-RX-API-DMAC7.html)
JP2021503455A5 (cg-RX-API-DMAC7.html)
JP2023538945A5 (cg-RX-API-DMAC7.html)
JP2024156657A5 (cg-RX-API-DMAC7.html)
JP2021515798A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2018522888A5 (cg-RX-API-DMAC7.html)
JP2017504578A5 (cg-RX-API-DMAC7.html)
JP2021520832A5 (cg-RX-API-DMAC7.html)
JP2015519375A5 (cg-RX-API-DMAC7.html)
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
HRP20241013T1 (hr) Protutijela za kelatirane radionuklide
JP2009225799A5 (cg-RX-API-DMAC7.html)
JP2023551027A5 (cg-RX-API-DMAC7.html)
JP2022545647A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2021502984A5 (cg-RX-API-DMAC7.html)
JP2019512207A5 (cg-RX-API-DMAC7.html)
JP2023520969A5 (cg-RX-API-DMAC7.html)
IL280487B2 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use